COVID-19 and diabetes mellitus : A need for prudence in elderly patients from a pooled analysis
Copyright © 2020 Diabetes India. All rights reserved..
OBJECTIVE: The objective of this study was to evaluate the pooled estimate of diabetes prevalence in young (<50 years) versus elderly (>50 years) COVID-19 cohorts.
METHODS: Studies published between December-2019 and March-2020 reporting demographic and clinical characteristics of COVID-19 cases were identified. A total of 11 studies included accounting for 2084 COVID-19 patients.
RESULTS: The overall prevalence of diabetes in COVID-19 patients with a mean age>50 years was 13.2%, whereas studies with relatively younger patients (mean age <50 years) had a pooled prevalence of 9.0% CONCLUSION: The overall prevalence of diabetes in COVID-19 patients was found to be 13.2% with studies including relatively elderly patients showing higher rates of diabetes. The intermingled effects of diabetes with other cardiovascular comorbidities warrant age-specific outcomes data including the impact of ongoing antidiabetic treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:14 |
|---|---|
| Enthalten in: |
Diabetes & metabolic syndrome - 14(2020), 4 vom: 01. Juli, Seite 683-685 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Desai, Rupak [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antidiabetic treatment |
|---|
| Anmerkungen: |
Date Completed 27.07.2020 Date Revised 29.09.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.dsx.2020.05.021 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM310206014 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM310206014 | ||
| 003 | DE-627 | ||
| 005 | 20231225135601.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.dsx.2020.05.021 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1033.xml |
| 035 | |a (DE-627)NLM310206014 | ||
| 035 | |a (NLM)32438333 | ||
| 035 | |a (PII)S1871-4021(20)30140-5 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Desai, Rupak |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a COVID-19 and diabetes mellitus |b A need for prudence in elderly patients from a pooled analysis |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 27.07.2020 | ||
| 500 | |a Date Revised 29.09.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Diabetes India. All rights reserved. | ||
| 520 | |a OBJECTIVE: The objective of this study was to evaluate the pooled estimate of diabetes prevalence in young (<50 years) versus elderly (>50 years) COVID-19 cohorts | ||
| 520 | |a METHODS: Studies published between December-2019 and March-2020 reporting demographic and clinical characteristics of COVID-19 cases were identified. A total of 11 studies included accounting for 2084 COVID-19 patients | ||
| 520 | |a RESULTS: The overall prevalence of diabetes in COVID-19 patients with a mean age>50 years was 13.2%, whereas studies with relatively younger patients (mean age <50 years) had a pooled prevalence of 9.0% CONCLUSION: The overall prevalence of diabetes in COVID-19 patients was found to be 13.2% with studies including relatively elderly patients showing higher rates of diabetes. The intermingled effects of diabetes with other cardiovascular comorbidities warrant age-specific outcomes data including the impact of ongoing antidiabetic treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Meta-Analysis | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Antidiabetic treatment | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a Diabetes mellitus | |
| 650 | 4 | |a Elderly | |
| 650 | 4 | |a Prevalence | |
| 650 | 4 | |a Type-2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Singh, Sandeep |e verfasserin |4 aut | |
| 700 | 1 | |a Parekh, Tarang |e verfasserin |4 aut | |
| 700 | 1 | |a Sachdeva, Sonali |e verfasserin |4 aut | |
| 700 | 1 | |a Sachdeva, Rajesh |e verfasserin |4 aut | |
| 700 | 1 | |a Kumar, Gautam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes & metabolic syndrome |d 2007 |g 14(2020), 4 vom: 01. Juli, Seite 683-685 |w (DE-627)NLM189445564 |x 1878-0334 |7 nnns |
| 773 | 1 | 8 | |g volume:14 |g year:2020 |g number:4 |g day:01 |g month:07 |g pages:683-685 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.dsx.2020.05.021 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 14 |j 2020 |e 4 |b 01 |c 07 |h 683-685 | ||